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Anti-carbamylated protein antibodies:
a specific hallmark for rheumatoid
arthritis. Comparison to conditions known
for enhanced carbamylation; renal failure,
smoking and chronic inflammation
Antibodies that target carbamylated proteins (anti-CarP
antibodies) have been described as a biomarker in rheumatoid
arthritis (RA).1 However, little is known about the factors that
predispose to the production of anti-CarP antibodies.
Carbamylation is a posttranslational modification resulting from
the conversion of lysines into homocitrullines that requires the
presence of cyanate. There are several conditions in which the
concentration of cyanate (and therefore carbamylation) is
increased, such as renal failure, chronic inflammation and heavy
smoking.2–4 We therefore addressed the question whether con-
ditions of enhanced carbamylation could result in the induction
of anti-CarP antibodies.
To investigate this, we determined the presence of anti-CarP
antibodies in serum samples from patients with renal failure,5
inflammatory bowel disease (IBD)6 and in heavy smokers with
or without chronic obstructive pulmonary disease (COPD)7 (see
table 1). The presence of anti-CarP antibodies in healthy con-
trols and patients with RAwas used as a comparison.1 8 The col-
lection of these cohorts was approved by the Leiden University
Medical Center ethics committee and informed consent was
obtained from all patients. Anti-CarP IgG and IgA antibodies
were determined by ELISA using carbamylated fetal calf serum
as antigen.1 Positivity for the presence of anti-CarP antibodies
was defined as signal higher than the 97th percentile of the
healthy controls. Each cohort was tested separately for this
study and control samples (between 120 and 187) were ran-
domly selected from a pool of 209 controls and taken along
with each measurement. The anti-CCP2 ELISA (anti-cyclic
citrullinated peptide) was carried out as described before.9
The percentage of individuals positive for anti-CarP anti-
bodies was 2.3%, 4.1%, 3.7%, 11.9% and 44.9% for controls,
smokers (no differences were observed in anti-CarP antibodies
between smokers with and without COPD) and patients with
IBD, renal failure and RA, respectively (figure 1A). Pearson χ2
test analyses revealed that a statistically increased frequency of
antibody positivity was found in RA (p=<0.001) and in
patients suffering from renal failure (p=0.004), when compared
with controls.
As a comparison to the presence of anti-CarP antibodies, a
second autoantibody, targeting a structurally similar antigen,
namely anti-CCP2, was measured. The percentages of indivi-
duals positive for anti-CCP2 antibodies were 1.5%, 1.9%,
0.5%, 2.4% and 50.5% for controls, smokers and patients with
IBD, renal failure and RA, respectively (figure 1B). These data
indicate that anti-CCP2 antibodies are present in patients with
RA but hardly in any of the other conditions. While in patients
with RA a certain extent of cross-reactivity between anti-CarP
and anti-CCP2 antibodies can be observed, there was no




Patients Number 374 433 85 120–187 557
Age Average (SD) 65 (9) 44 (14) 54 (13) 44 (14) 57 (16)
Gender Percentage
female
27 58 29 51 67
Smoking Percentage
current
42 21 24 8 23
Pack years
(average)
39 n.d. n.d. n.d. n.d.
For the controls, the values are given for the total group of 209 controls. For the assays,
controls were randomly selected out of the group of 209 controls. Controls were not
age matched or gender matched. We did not observe a correlation between
anti-carbamylated protein antibodies and age or gender.
Data from patients with RA as in reference (1).
IBD, inflammatory bowel disease; n.d., not determined; RA, rheumatoid arthritis.
Figure 1 Anti-CarP and anti-CCP2 antibody positivity. (A) The percentage of anti-CarP IgG antibody positivity in each of the tested cohorts is shown.
When compared with controls, significant differences were observed for RA (p<0.001) and renal failure (p=0.004). (B) The percentage of anti-CCP2
antibody positivity in each of the tested cohorts is shown. When compared with controls, significant differences were observed for RA (p<0.001). For
both, control percentages are an average of all measurements. (C) The percentage of anti-CarP IgA positivity in each of the tested cohorts is shown.
When compared with controls, significant differences were observed for RA (p<0.001), renal failure (p=0.048) and smoking (p=0.026). (D) Overlap
between anti-CarP IgA and anti-CCP2 IgG antibodies. Groups were divided based on antibody positivity. Percentages of the patients with RA are
shown as determined in reference (1). Anti-CarP, Anti-carbamylated protein; IBD, inflammatory bowel disease; RA, rheumatoid arthritis.
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overlap between these autoantibodies in renal failure, smoking
or IBD (figure 1D). Therefore, the presence of a (low) percent-
age of anti-CarP IgG antibodies in the individuals analysed is
not due to the presence of anti-CCP2 antibodies.
Both IBD and smoking might involve more carbamylation in
the lungs or intestine, in which IgA antibodies are thought to be
more prevalent than IgG antibodies. Therefore, anti-CarP IgA
antibodies were determined as shown in figure 1C (2.7%, 7.8%,
4.6%, 7.9% and 43% for controls, smokers and patients with
IBD, renal failure and RA, respectively). Compared with con-
trols, positivity in patients with RA, renal failure and smoking
was statistically significant. When correcting for multiple testing,
only the difference between controls and patients with RA
remained significant.
In summary, we observed an increase in anti-CarP antibodies
in patients with RA and to a lesser extent in patients suffering
from renal disease. Since an increase in anti-CarP antibodies was
not detected in other conditions with enhanced carbamylation,
we conclude that increased carbamylation alone is not sufficient
for a break of tolerance against carbamylated proteins.
Therefore, our data indicate that next to carbamylation, also
other (genetic or environmental) factors are required for the
induction of anti-CarP antibodies.
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